The antibiotic combination sulbactam-durlobactam (sul-dur; Xacduro, Innoviva Specialty Therapeutics) was approved on May 23, 2023, to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex, filling a major therapeutic need in infectious disease.
“This is very exciting news for all of us in the field of infectious diseases,” said Yi Guo, PharmD, the co-director